A Former WaPo Exec on What He Learned From Jeff Bezos
Jarrod Dicker, WaPo’s former VP of innovation and commercial, learned one trick from business magnate Jeff Bezos that’s propelled his career: focus on what you know how to do best, and don’t worry about the competition.
“Two times the experimentation equals two times the innovation,” Dicker said in an interview with Cheddar. “Really doubling down on what we believe in and getting the right people to do that with you opens up a new wave of opportunities.”
Bezos, the CEO of Amazon, bought the Washington Post in 2013 and his influence there is strong. Dicker said that during his tenure, he saw the effects of “Bezosism” on employees’ thought processes.
Dicker took that knowledge to his current company Po.et, a blockchain-supported content platform.
“At the Post we built a team called RED, which was Research, Experimentation, and Development, that focused on building new technologies and licensing them to help build a better economy for all media companies,” he said. “The reason I left to do this is because this is a direct follow of the work that I’ve done there and what I could do next.”
For the full interview, [click here](https://cheddar.com/videos/tracking-content-on-blockchain-with-po-et).
Smoke that filled the cabin of a Delta flight as it took off from the Atlanta airport in February was so thick the led flight attendant had trouble seeing past the first row of passengers and the pilots donned oxygen masks as a precaution.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
